Oruka Therapeutics Q2 FY26 net loss widens to $41.2 million; R&D expenses rise to $43.3 million

• Oruka posted a Q2 2026 net loss of $41.2 million, widening from $24.6 million a year earlier.
• R&D expenses climbed to $43.3 million from $24.1 million, driven by added trials, a Halozyme upfront payment, higher compensation.
• G&A expenses rose to $6.9 million from $4.3 million, while other income increased to $8.9 million from $3.9 million on higher interest.
• Cash, cash equivalents and marketable securities totaled $1.1 billion as of June 30, 2026, expected to fund operations through a planned ORKA-001 BLA filing.
• EVERLAST-A Week 28 data due end-3Q 2026; EVERLAST-B enrolled 187 with Week 16 data expected in 4Q 2026 to support a Phase 3 start in 1H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-086933), on August 10, 2026, and is solely responsible for the information contained therein.